The clinical study of Xiaoaiping tablet combined AP regimen in the treatment of unresectable advance endometrial carcinoma
10.3760/cma.j.issn.1673-4246.2018.12.006
- VernacularTitle:消癌平片辅助化疗治疗晚期子宫内膜癌
- Author:
Hui ZHONG
1
;
Min LIU
;
Liying LIU
;
Xiaohong REN
;
Jie DANG
;
Shuyun QU
;
Juan ZHANG
;
Jing LIU
Author Information
1. 陕西省核工业215医院妇科
- Keywords:
Carcinoma;
endometrioid;
Antineoplastic combined chemotherapy protocols;
Xiaoaiping tablet;
Drug-related side effects and adverse reactions;
Immunity;
cellular;
Survival rate;
Disease-free survival;
Quality of life
- From:
International Journal of Traditional Chinese Medicine
2018;40(12):1129-1133
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical study of Xiaoaiping tablet combined AP regimen in the treatment of unresectable advance endometrial carcinoma. Methods A total of 268 patients with advance endometrial carcinoma in our hospital were divided into treatment group and control group, 134 cases in each group. The control group was treated by AP regimen and the treatment group was given Xiaoaiping tablet combined AP regimen. The treatment was 3 weeks per course, 4 periods performance, and the 2 year follow-up. After the treatment, the immune index, including IgG, IgA, IgM, CD3+ and CD4+ were detected by a chemical lighting method in the 2 groups. The KPS scores were observed to evaluate the life quality in the 2 groups. During the treatment, the adverse effects of chemotherapy in patients were observated during the treatment. And the survival rates, overall survival and progression-freely-survival were also observed. Results After the treatment, the control rate and efficiency rate were 86.5％ (116/134) and 64.2％(86/134) in treatment group, while the control rate and efficiency rate were 76.9％ (103/134) and 52.2％(70/134) in control group, where there were significantly difference in control rate and efficiency rate (Z values were 3.542 and 3.871, P values were 0.041 and 0.039). After the treatment, the levels of IgG, Ig A, IgM, CD3+ and CD4+ in treatment group were significantly higher than control group (t values were 4.725, 4.930, 4.259, 4.571 and 4.006, P<0.01). After the 1st-4th period of treatment, the KPS scores in treatment group were significantly higher than the control group (t values were 3.124, 3.452, 3.612 and 3.712, P<0.05). After the treatment, the PFS, OS, 1 year survival rate and 2 year survival rate were significantly lower in treatment group than control group (t values were 4.241, 4.421, 3.735 and 3.982, P<0.05). Conclusions The Xiaoaiping tablet combined AP regimen in the treatment of unresectable advance endometrial carcinoma has a good effect, could promote the immune function, decease the adverse effects and prolong the survival time in the patients.
